A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Inclusion Criteria: * Signed the informed consent. * Female aged ≥18 years old. * Histologically diagnosed patients with recurrent and metastatic triple negative breast cancer. * No more than 2-line chemotherapy failed at the stage of recurrence and metastasis . * Patients who have been treated with platinum-based regimen at the stage of recurrence/metastasis need non-disease progression (non-pd)during treatment * At least one measuring lesion that confirmed by RECIST v1.1 standard. * The patients can swallow pills. * Have a life expectancy of at least 12 weeks. * The functions of vital organs meet protocal requirements. Exclusion Criteria: * Subjects had any history of active autoimmune disease . * Subjects had previously been treated with anti-PD-1 and PD-L1 antibodies, or was known to be allergic to antibody drugs, or had previously been treated with apatinib, or had previously been treated with PARP inhibitors. * Subjects have untreated central nervous system metastasis. * History of hypertension and antihypertensive medications are not well controlled. * Some clinical symptoms or diseases of the heart that are not well controlled. * History of immunodeficiency including HIV-positive. * Subjects had active infections.